This Reproductive Health Company's Weekly Contraceptive Patch Can Reach Millions Of Women Thanks To A Partnership With Afaxys
SponsoredAgile Therapeutics Partners With Telehealth Platforms To Expand Access To Weekly Birth Control Patch To Millions Of Women
SponsoredAgile Sees Renewed Hope For Even Broader Adoption Of Its Weekly Birth Control Patch After Biden's Latest Executive Order Expanding Contraceptive Coverage
SponsoredH.C. Wainwright Reiterates Buy Rating For Agile Therapeutics (NASDAQ: AGRX), Citing Growing Demand For Twirla, A Weekly Low Dose Birth Control Patch
SponsoredAgile Therapeutics Recent News
This Women's Healthcare Company Raised $7.5 Million In A Public Offering And Says It's Targeting $25 To $30 Million Net Revenue By End Of 2023
Sponsored
Agile Therapeutics – This Women's Healthcare Company's "Skinfusion" Technology Sets It Apart From Other Contraceptive Companies
Sponsored
Agile Therapeutics Expects Its Innovative Once-A-Week Birth Control Patch To Drive Revenues Of $25-30 Million In 2023 – What Is The Hype All About?
Sponsored
The Overturning of Roe v. Wade Has Changed The Landscape Of Birth Control; Smaller Companies Are Now An Integral Part Of Care
Sponsored
Agile Therapeutics: The CEO Of This Women's Healthcare Company That Recently Saw Revenue Growth Of 33% Speaks To Benzinga
Sponsored
Agile Therapeutics: This BioPharma Firm Is Nimbly Solving Unmet Needs For Women
Sponsored
This Biotech Company is Pursuing Positive Cash Flow In 2023
Sponsored
Women's Healthcare Company Agile Therapeutics Says It Believes It Has An Effective Business Plan In Place For Growth And Generating Positive Cash Flow
Sponsored
Can This Company's Birth Control Patch Disrupt The Contraceptive Market?
Sponsored
The Past Week's Notable Insider Buys Included Digitalbridge, Life Time, A SPAC And More
Agile Therapeutics Plunges After Company Prices A Stock Offering At $6.35 Per Share